Navigation Links
Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
Date:4/7/2008

BERKELEY HEIGHTS, N.J., April 7, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that presentations related to Genasense(R) (oblimersen sodium) Injection, the Company's lead anticancer compound will be featured at the annual meeting of the American Association for Cancer Research (AACR). The meeting will be held in San Diego, CA from April 12-16, 2008. The subject matter of several abstracts, which are relevant to both the Company's ongoing randomized Phase 3 trial of Genasense in patients with advanced melanoma, and also to any subsequent regulatory filings that may ensue from that trial, include the following:

Pharmacokinetics (PK) of oblimersen in subjects with mild and moderate renal impairment. Authors: Quereshi A, et al.

Summary: Describes the PK of Genasense in patients with impaired kidney function that may be relevant for prescribers.

Poster session: Sunday, April 13, 2008; 8:00 am.

Population pharmacokinetics (PK) of dacarbazine and Genasense in adult patients with advanced melanoma. Authors: Rezai K, et al.

Summary: Describes the PK of both Genasense and dacarbazine (the chemotherapy drug given to all patients in the Phase 3 melanoma study) and how these drugs interact when co-administered in human subjects.

Poster session: Sunday, April 13, 2008; 8:00 am.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat var
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
7. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
8. FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
9. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... Oil Market by Extraction type (SFE, Cold Pressed, ... Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - ... MarketsandMarkets, defines and segments the Amaranth Seed Oil ... market size in terms of value. The Amaranth ...
(Date:8/29/2014)... 29, 2014   Vittamed Corporation , a neurodiagnostics medical ... today that T. (Teo) Forcht Dagi , MD, DmedSc, ... of Directors. " Teo Forcht Dagi ... medical innovation and venture capital," said Remis Bistras , ... add his clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... PITTSBURGH , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage ... at the Australian and New Zealand Forensic Science ... Forensic Sciences in Adelaide, Australia ... discussion concerning the advancements that hyperspectral imaging can ... Jeffrey Beckstead , Director of Product Development ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... (NASDAQ: IPHS ), the leading North American ... pharmaceutical, oral care and industrial end markets, today announced ... completed the acquisition of Kelatron Corporation. Kelatron ... of bioactive mineral nutrients. For over 30 years, the ...
... Filtrona Porous Technologies, a developer and manufacturer of custom ... will introduce a new range of hydrophilic, polyurethane foams ... COMPAMED trade fair in Dusseldorf, Germany from 16 to ... New innovations to be featured at ...
Cached Medicine Technology:Innophos Holdings, Inc. Announces Acquisition of Kelatron Corporation 2Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair 2
(Date:9/1/2014)... 01, 2014 An operating theatre or ... for performing surgical operations. An operating room comprises a ... booms, operating room lights, imaging displays as well as ... by Transparency Market Research, a U.S.-based market research firm, ... USD 4.5 billion by 2019. , According to ...
(Date:9/1/2014)... "Women struggle with weight gain typically associated to ... early as 15, if not earlier. Women therefore ... downs of hormone related weight gain. The battle ... to rage against the hidden and ever-present hormones which ... begin to face menopause and related changes, these hormonal ...
(Date:9/1/2014)... By Dennis Thompson ... -- An experimental Ebola drug previously given to two American ... the deadly virus in laboratory tests, researchers report. The ... it, even if they didn,t get the medication until five ... cases of Ebola who were days or even hours away ...
(Date:9/1/2014)... atrial fibrillation (AF) doubles the risk of stroke compared ... 6 000 patients presented at ESC Congress today by ... a simple clinical assessment of the type of AF ... Ischaemic stroke is the second cause of death in ... many more disabled patients each year. Annual direct health ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The National ... to announce that Dawn Bazarko, DNP, MPH, RN, and ... of the American Academy of Nursing. They will be ... RN-BC, CCM, FACHE, whose induction we reported last May. ... 18, 2014, during the 2014 American Academy of Nursing ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4
... go indoors, , , SATURDAY, July 12 (HealthDay News) -- Summer ... so it is also the time for them to be ... is, ,When thunder roars, go indoors," Mary Ann Cooper, director ... Illinois at Chicago, said in a prepared statement. "Decisions about ...
... Emageon Inc.,(Nasdaq: EMAG ), a leader ... networks and imaging facilities,announced today that the Strategic ... Jefferies and Company as Lead Advisor and SunTrust,Robinson ... it evaluates all,strategic options available to the company., ...
... MANHATTAN BEACH, Calif., July 11 A,democratic process involving ... July 14 with hearings to determine the best way ... have the greatest strength,to win for their families and ... step in a thorough, open, and democratic,discussion to make ...
... $500 million in cuts, WASHINGTON, July 11 ... and pay more out of pocket,for health care, while ... legislation approved this week by the U.S. Congress., ... from the,Medicare Advantage program over a five-year period, including ...
... Texas, July 11 Abuelo,s restaurants today,released the ... been linked to consumption of certain raw jalapeno ... recommendation of the Centers for Disease Control (CDC),Abuelo,s ... our recipes and,plate presentations at this time. We ...
... In New York, the majority of Medicaid LTC Funds ... A new report by AARP,s,Public Policy Institute finds mixed ... long-term care (LTC) options under Medicaid.,According to the report, ... Medicaid LTC dollars for older people providing home and ...
Cached Medicine News:Health News:Summer Is Peak Time for Lightning Strikes 2Health News:Florida Seniors' Medicare Advantage Benefits at Risk 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 3
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Medicine Products: